Companies › Minerva Biotechnologies
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2035.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| huMNC2-CAR44 CAR T cells Anti-MUC1* (cleaved MUC1) CAR T cell therapy | MUC1 | Phase 1 | Metastatic Breast Cancer | Jan 2035 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04020575 | huMNC2-CAR44 CAR T cells | Phase 1 | Metastatic Breast Cancer | Oncology | Jan 2035 |
| NCT04020575 | huMNC2-CAR44 CAR T cells | Phase 1 | Metastatic Breast Cancer | Oncology | Jan 2035 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.